|
|||||
|
|
Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States |
|
| Authors: | Odette S. Reifsnider PhD Pratik Pimple PhD Sarah Brand MSc Evelien Bergrath Washington MSc Sharash Shetty PhD Nihar R. Desai MD |
| Affiliation: | 1. Evidera, Bethesda, Maryland;2. Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut;3. Evidera, Waltham, Massachusetts;4. Yale School of Medicine, Cardiovascular Medicine, New Haven, Connecticut |
| Abstract: | |
| Keywords: | cardiovascular disease cost-effectiveness empagliflozin GLP-1 liraglutide SGLT-2 inhibitor |